GlassScriptPhysician profile
Rohan T Mehta
NPI 1760809073
$3,513.23
in general payments reported to CMS, 2019-2025
22 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $1,105 · 2021: $135 · 2022: $192 · 2023: $161 · 2024: $593 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,359.20 | 2019-2025 | General - Embolics, Embold Fibered, Icefx Cryoablation System |
| Inari Medical, INC. | $474.33 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $461.76 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $235.95 | 2023-2025 | |
| Pfizer INC. | $108.11 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.05 | 2021-2025 | Jardiance |
| Medtronic, INC. | $91.20 | 2021-2025 | Emprint, Linq II |
| Medtronic Vascular, INC. | $75.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.01 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $72.80 | 2022-2025 | Camzyos, Eliquis |
| Janssen Biotech, INC. | $67.09 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $64.29 | 2023-2025 | Verquvo, Keytruda, Lynparza |
| Lantheus Medical Imaging, INC. | $52.71 | 2022-2025 | |
| Amgen INC. | $51.65 | 2021-2025 | Repatha |
| Novo Nordisk INC | $42.57 | 2024 | Ozempic, Rybelsus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.31 | 2022-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.41 | 2023-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $26.52 | 2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $23.59 | 2024 | Optimizer |
| Esperion Therapeutics, INC. | $22.44 | 2025 | Nexletol |
| Abiomed | $21.27 | 2022 | |
| Amarin Pharma, INC. | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.